NASDAQ · Healthcare · Financials
Amgen Inc. (AMGN) Financial Statements: Income, Balance Sheet & Cash Flow
Revenue, profitability, balance-sheet strength, and cash generation for AMGN. SEC filings, statements through Jun 30, 2026.
Section freshness
Prices as of Sep 8, 2:13 PM EDT · Fundamentals checked Sep 8, 2:02 PM EDT · Statements Jun 30, 2026
Financial read
AMGN latest financial snapshot.
Start with the latest reported values below. Deeper quarterly and annual statement tables follow when supplied.
Revenue
$10.05B
+9.5% YoY
Net income
$2.38B
+30.6% QoQ
Free cash flow
$3.49B
+136.2% QoQ
Net margin
23.62%
Operating margin 34.95%
Balance sheet coverage
AMGN balance sheet summary
Assets, liabilities, liquidity, debt, and equity sit beside income and cash-flow tables so the statement history reads as one model-ready dataset.
20 quarterly · 4 annual rows · Market data source · as of 2026-06-30
Latest period
Q2 FY2026
20 quarterly · 4 annual rows
Assets / liabilities
$95.64B
Liabilities —
Cash / debt
$13.99B
Net cash -$37.87B
Equity / working capital
$11.69B
Working capital $9.46B
Financial statements
AMGN statement coverage.
Income statement, balance sheet, and cash-flow figures for AMGN, with quarterly and annual history in the tables below.
Data last updated
Jun 29, 2026
Income periods
24
Balance-sheet periods
24
Cash-flow periods
24
Quarterly and annual AMGN statements, sourced from SEC filings, statements through Jun 30, 2026.
Financial statement period
AMGN statement history
SEC filings, statements through Jun 30, 2026 · Data last updated: Jun 29, 2026
Income statement
Quarterly and annual rows for revenue, operating leverage, earnings quality, and margin direction.
| Period | Revenue | Operating income | Net income | Net margin | Revenue QoQ | Net income QoQ |
|---|---|---|---|---|---|---|
| Q2 FY2026 | $10.05B | $3.51B | $2.38B | 23.62% | +16.7% | +30.6% |
| Q1 FY2026 | $8.62B | $2.67B | $1.82B | 21.11% | -12.6% | +36.5% |
| Q4 FY2025 | $9.87B | $2.72B | $1.33B | 13.51% | +3.2% | -58.6% |
| Q3 FY2025 | $9.56B | $2.53B | $3.22B | 33.65% | +4.1% | +124.6% |
| Q2 FY2025 | $9.18B | $2.66B | $1.43B | 15.60% | +12.6% | -17.2% |
| Q1 FY2025 | $8.15B | $1.18B | $1.73B | 21.23% | -10.3% | +175.9% |
| Q4 FY2024 | $9.09B | $2.31B | $627.00M | 6.90% | +6.9% | -77.8% |
| Q3 FY2024 | $8.50B | $2.05B | $2.83B | 33.28% | +1.4% | +279.4% |
Balance sheet
Balance-sheet history for assets, liabilities, liquidity, debt, equity, and shares outstanding.
| Period | Cash | Current assets | Current liabilities | Total assets | Total debt | Total equity | Debt QoQ |
|---|---|---|---|---|---|---|---|
| Q2 FY2026 | $13.99B | $34.96B | $25.50B | $95.64B | $51.86B | $11.69B | -0.1% |
| Q1 FY2026 | $12.04B | $31.48B | $24.95B | $92.50B | $51.89B | $9.19B | +3.8% |
| Q4 FY2025 | $9.13B | $29.06B | $25.49B | $90.59B | $50.01B | $8.66B | -4.6% |
| Q3 FY2025 | $9.45B | $27.89B | $21.79B | $90.14B | $52.43B | $9.62B | -2.5% |
| Q2 FY2025 | $8.03B | $26.73B | $20.48B | $87.90B | $53.76B | $7.43B | -0.5% |
| Q1 FY2025 | $8.81B | $26.93B | $23.01B | $89.37B | $54.01B | $6.21B | -4.5% |
| Q4 FY2024 | $11.97B | $29.03B | $23.10B | $91.84B | $56.55B | $5.88B | -0.5% |
| Q3 FY2024 | $9.01B | $26.77B | $20.31B | $90.88B | $56.85B | $7.53B | -0.5% |
Cash flow
Operating cash generation, capital expenditure, free cash flow, buybacks, dividends, and cash movement.
| Period | Operating cash flow | CapEx | Free cash flow | Net income | Dividends paid | Buybacks | FCF QoQ |
|---|---|---|---|---|---|---|---|
| Q2 FY2026 | $4.00B | $513.00M | $3.49B | $2.38B | $1.36B | +136.2% | |
| Q1 FY2026 | $2.19B | $712.00M | $1.48B | $1.82B | $1.36B | +53.7% | |
| Q4 FY2025 | $1.60B | $642.00M | $961.00M | $1.33B | $1.28B | -77.4% | |
| Q3 FY2025 | $4.68B | $436.00M | $4.25B | $3.22B | $1.28B | +122.3% | |
| Q2 FY2025 | $2.28B | $369.00M | $1.91B | $1.43B | $1.28B | +95.0% | |
| Q1 FY2025 | $1.39B | $411.00M | $980.00M | $1.73B | $1.28B | -77.7% | |
| Q4 FY2024 | $4.77B | $371.00M | $4.40B | $627.00M | $1.21B | +32.8% | |
| Q3 FY2024 | $3.57B | $257.00M | $3.31B | $2.83B | $1.21B | +49.2% |
Valuation and returns
- Enterprise value
- $252.86B
- TECHi computed
- Return on equity
- 74.80%
- Market data source · as of 2026-09-08
- Return on assets
- 9.14%
- Market data source · as of 2026-09-08
- Debt / equity
- 4.44
- Current ratio 1.37
Ratio values use provider-attributed fields when available and otherwise fall back to TECHi statement math from the visible rows on this page.
Annual revenue and income multiples
Annual sales and income multiple reads use the latest annual statement when available, then fall back to trailing-twelve-month statement math from the visible quarterly rows.
- Annual revenue base
- $36.75B
- Annual statement 2025-12-31
- Annual income base
- $7.71B
- Annual statement 2025-12-31
- Market cap / annual revenue
- 5.85
- Live market value divided by annual revenue
- Market cap / annual income
- 27.88
- Live market value divided by annual net income
Annual sales and income multiple
Market capitalization bridge
TTM valuation multiples
- TTM revenue
- $38.09B
- Trailing twelve months
- TTM EBIT
- $11.43B
- TTM operating income
- Market cap / TTM revenue
- 5.64
- Live market value divided by trailing twelve months revenue
- EV / TTM revenue
- 6.64
- Enterprise value divided by trailing twelve months revenue
Live market value is matched against trailing-twelve-month statement bases first so the multiple moves with the tape instead of anchoring to stale fiscal-year rows.
Profit multiples
Revenue, net income, and free cash flow
Quarterly statement rows, shown on one common dollar scale so margin compression and cash conversion stand out quickly.
Efficiency
- Revenue / employee
- $1.21M
- 31,500 employees
- Net income / employee
- $277,555.556
- TTM net income divided by employees
- FCF / employee
- $323,015.873
- TTM free cash flow divided by employees
- Market cap / employee
- $6.83M
- Live value per employee
Growth vs cost pressure
Cash conversion
TTM free cash flow / TTM operating income
Quarterly margin heatmap
Latest quarter expense mix
Profit bridge
Other income statement lines
Balance sheet · Q2 FY2026
- Cash & equivalents
- $13.99B
- Total debt
- $51.86B
- Net cash
- -$37.87B
- Net debt position
- Total equity
- $11.69B
Balance sheet detail
- Current assets
- $34.96B
- Current liabilities
- $25.50B
- Inventory
- $6.22B
- Receivables
- $10.23B
- Property, plant & equipment
- $8.55B
- Long-term debt
- $51.86B
Debt and liquidity
Cash + short-term investments + receivables / current liabilities
Cash generation
- Operating cash flow
- $4.00B
- Capital expenditure
- $513.00M
- Free cash flow
- $3.49B
- Capital returned
- $1.36B
- Buybacks + dividends paid
Cash-flow detail
- Depreciation & amortization
- $1.11B
- Investing cash flow
- -$569.00M
- Financing cash flow
- -$1.48B
- Dividends paid
- $1.36B
Cash flow read
AMGN converts most of its earnings into cash.
Free cash flow of $3.49B versus $2.38B of reported net income means accruals aren't doing much heavy lifting — the cash is showing up alongside the earnings. That's the cleanest profile a fundamentals desk wants to see.
Frequently asked
Common questions.
What financial data is available for AMGN?
TECHi shows Amgen Inc.'s income statement, balance sheet, and cash-flow statement by reported period, with each figure attributed to its source. Line items the company does not report are left blank rather than estimated.
How current are AMGN's financial statements?
Each AMGN statement is labelled with its reported period and source, so you can see exactly which quarter or fiscal year a figure covers and when the data was last updated.
What is Amgen Inc.'s reported net margin?
Amgen Inc. reports a net margin of 22.95% in its latest available fundamentals; the statements below show the revenue and cost lines behind it.